|
1
|
Heppner G, Yamashina K, Miller B and
Miller F: Tumor heterogeneity in metastasis. Prog Clin Biol Res.
212:45–59. 1986.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gadducci A, Sartori E, Maggino T, Zola P,
Landoni F, Fanucchi A, Palai N, Alessi C, Ferrero AM, Cosio S and
Cristofani R: Analysis of failures after negative second-look in
patients with advanced ovarian cancer: An Italian multicenter
study. Gynecol Oncol. 68:150–155. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bagnato A and Rosanò L:
Epithelial-mesenchymal transition in ovarian cancer progression: A
crucial role for the endothelin axis. Cells Tissues Organs.
185:85–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: Biology, endocrinology and
pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lafky JM, Wilken JA, Baron AT and Maihle
NJ: Clinical implications of the ErbB/epidermal growth factor (EGF)
receptor family and its ligands in ovarian cancer. Biochim Biophys
Acta. 1785:232–265. 2008.PubMed/NCBI
|
|
8
|
Lassus H, Sihto H, Leminen A, Joensuu H,
Isola J, Nupponen NN and Butzow R: Gene amplification, mutation,
and protein expression of EGFR and mutations of ERBB2 in serous
ovarian carcinoma. J Mol Med (Berl). 84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagano O and Saya H: Mechanism and
biological significance of CD44 cleavage. Cancer Sci. 95:930–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim Y, Lee YS, Choe J, Lee H, Kim YM and
Jeoung D: CD44-epidermal growth factor receptor interaction
mediates hyaluronic acid-promoted cell motility by activating
protein kinase C signaling involving Akt, Rac1, Phox, reactive
oxygen species, focal adhesion kinase and MMP-2. J Biol Chem.
283:22513–22528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murai T, Miyauchi T, Yanagida T and Sako
Y: Epidermal growth factor-regulated activation of Rac GTPase
enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.
Biochem J. 39:65–71. 2006. View Article : Google Scholar
|
|
12
|
Ellis IR, Schor AM and Schor SL: EGF AND
TGF-alpha motogenic activities are mediated by the EGF receptor via
distinct matrix-dependent mechanisms. Exp Cell Res. 313:732–741.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grass GD, Tolliver LB, Bratoeva M and
Toole BP: CD147, CD44, and the epidermal growth factor receptor
(EGFR) signaling pathway cooperate to regulate breast epithelial
cell invasiveness. J Biol Chem. 288:26089–26104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Judd NP, Winkler AE, Murillo-Sauca O,
Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and
Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer
aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frémin C and Meloche S: From basic
research to clinical development of MEK1/2 inhibitors for cancer
therapy. J Hematol Oncol. 3:82010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu
Y, Wang J, Ding X and Gao F: Sorafenib inhibits
epithelial-mesenchymal transition through an epigenetic-based
mechanism in human lung epithelial cells. PLoS One. 8:e649542013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu D, Wolf JK, Scanlon M, Price JE and
Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer
cells correlates with more severe malignancy that can be suppressed
by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
|
|
19
|
Buick RN, Pullano R and Trent JM:
Comparative properties of five human ovarian adenocarcinoma cell
lines. Cancer Res. 45:3668–3676. 1985.PubMed/NCBI
|
|
20
|
Yan L, Zucker S and Toole BP: Roles of the
multifunctional glycoprotein, emmprin (basigin; CD147), in tumour
progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
|
|
21
|
Marieb EA, Zoltan-Jones A, Li R, Misra S,
Ghatak S, Cao J, Zucker S and Toole BP: Emmprin promotes
anchorage-independent growth in human mammary carcinoma cells by
stimulating hyaluronan production. Cancer Res. 64:1229–1232. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Toole BP and Slomiany MG: Hyaluronan, CD44
and Emmprin: Partners in cancer cell chemoresistance. Drug Resist
Updat. 11:110–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
La Fleur L, Johansson AC and Roberg K: A
CD44high/EGFRlow subpopulation within head and neck cancer cell
lines shows an epithelial-mesenchymal transition phenotype and
resistance to treatment. PLoS One. 7:e440712012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grandis JR and Sok JC: Signaling through
the epidermal growth factor receptor during the development of
malignancy. Pharmacol Ther. 102:37–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim HR, Wheeler MA, Wilson CM, Iida J, Eng
D, Simpson MA, McCarthy JB and Bullard KM: Hyaluronan facilitates
invasion of colon carcinoma cells in vitro via interaction with
CD44. Cancer Res. 64:4569–4576. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cook AC, Chambers AF, Turley EA and Tuck
AB: Osteopontin induction of hyaluronan synthase 2 expression
promotes breast cancer malignancy. J Biol Chem. 281:24381–24389.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nedvetzki S, Gonen E, Assayag N, Reich R,
Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley
EA and Naor D: RHAMM, a receptor for hyaluronan-mediated motility,
compensates for CD44 in inflamed CD44-knockout mice: A different
interpretation of redundancy. Proc Natl Acad Sci USA.
101:18081–18086. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim MS, Park MJ, Kim SJ, Lee CH, Yoo H,
Shin SH, Song ES and Lee SH: Emodin suppresses hyaluronic
acid-induced MMP-9 secretion and invasion of glioma cells. Int J
Oncol. 27:839–846. 2005.PubMed/NCBI
|
|
29
|
Caudroy S, Polette M, Tournier JM, Burlet
H, Toole B, Zucker S and Birembaut P: Expression of the
extracellular matrix metalloproteinase inducer (EMMPRIN) and the
matrix metalloproteinase-2 in bronchopulmonary and breast lesions.
J Histochem Cytochem. 47:1575–1580. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weidle UH, Scheuer W, Eggle D, Klostermann
S and Stockinger H: Cancer-related issues of CD147. Cancer Genomics
Proteomics. 7:157–169. 2010.PubMed/NCBI
|
|
31
|
Toole BP: Hyaluronan-CD44 interactions in
cancer: Paradoxes and possibilities. Clin Cancer Res. 15:7462–7468.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jacobson A, Rahmanian M, Rubin K and
Heldin P: Expression of hyaluronan synthase 2 or hyaluronidase 1
differentially affect the growth rate of transplantable colon
carcinoma cell tumors. Int J Cancer. 102:212–219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan
ZK, Liu K and Huang S: Extracellular signal-regulated kinase
signaling pathway regulates breast cancer cell migration by
maintaining slug expression. Cancer Res. 69:9228–9235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boregowda RK, Appaiah HN, Siddaiah M,
Kumarswamy SB, Sunila S, Thimmaiah KN, Mortha K, Toole B and
Banerjee Sd: Expression of hyaluronan in human tumor progression. J
Carcinog. 5:22006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y and Heldin P: Hyaluronan production
increases the malignant properties of mesothelioma cells. Br J
Cancer. 85:600–607. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tamada Y, Takeuchi H, Suzuki N, Aoki D and
Irimura T: Cell surface expression of hyaluronan on human ovarian
cancer cells inversely correlates with their adhesion to peritoneal
mesothelial cells. Tumour Biol. 33:1215–1222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ricciardelli C, Ween MP, Lokman NA, Tan
IA, Pyragius CE and Oehler MK: Chemotherapy-induced hyaluronan
production: A novel chemoresistance mechanism in ovarian cancer.
BMC Cancer. 13:4762013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fitzgerald KA, Bowie AG, Skeffington BS
and O'Neill LA: Ras, protein kinase C zeta, and I kappa B kinases 1
and 2 are downstream effectors of CD44 during the activation of
NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. J
Immunol. 164:2053–2063. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dudgeon C, Peng R, Wang P, Sebastiani A,
Yu J and Zhang L: Inhibiting oncogenic signaling by sorafenib
activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Oncogene. 31:4848–4858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kurman RJ, Visvanathan K, Roden R, Wu TC
and Shih IeM: Early detection and treatment of ovarian cancer:
Shifting from early stage to minimal volume of disease based on a
new model of carcinogenesis. Am J Obstet Gynecol. 198:351–356.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gemignani ML, Schlaerth AC, Bogomolniy F,
Barakat RR, Lin O, Soslow R, Venkatraman E and Boyd J: Role of KRAS
and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol
Oncol. 90:378–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
